WebMar 9, 2024 · The trial was conducted among 237 adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed while on or after previous platinum-based chemotherapy and PD-(L)1 inhibitor immunotherapy4. Two Phase III CANOPY trials continue, evaluating canakinumab in first-line and adjuvant settings2,3. WebFeb 11, 2011 · It is the combination of platinum-based (cisplatin, carboplatin) chemotherapy AND docetaxel, paclitaxel, vinorelbine, gemcitabine or irinotecan ... based chemotherapy. ...platinum-doublet ...
5-Fu-Based Doublet Regimen in Patients Receiving Perioperative …
WebApr 10, 2013 · Patient has stage IIIB or IV diagnosis and must have received one or two prior regimens (including platinum- doublet) of cytotoxic chemotherapy for the treatment of locally advanced or metastatic NSCLC. Patient has at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a … WebObjective: Optimal second-line chemotherapy for patients with relapsed small-cell lung cancer remains debatable. In addition to topotecan or amrubicin monotherapy, re … scott hairdresser
The pan-immune-inflammation value is associated with clinical …
WebNov 2, 2024 · Platinum-based chemotherapy drugs are used to treat many types of cancer, including lung, breast, ovarian, and testicular cancer. Though effective, these drugs can … WebBackground: Colorectal cancer (CRC) patients have a better prognosis if metastases are resectable. Initially, unresectable liver-only metastases can be converted to resectable with chemotherapy plus a targeted therapy. We assessed which of chemotherapy doublet (2-CTx) or triplet (3-CTx), combined with targeted therapy by RAS status, would be better in … WebIntroduction: Patients with EGFR-mutant lung cancer who have had disease progression on osimertinib commonly receive platinum doublet chemotherapy, but whether adding immunotherapy or bevacizumab provides additional benefit is unknown. Materials and methods: This was a retrospective analysis at 2 university-affiliated institutions. . Patients … scott haire